Adverse events879

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 879

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	215	376	486
other	Nausea	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	185	363	395
other	Nausea	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	188	352	459
other	Diarrhoea	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	134	376	251
other	Diarrhoea	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	125	363	207
other	Diarrhoea	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	126	352	262
other	Vomiting	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	129	376	224
other	Vomiting	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	110	363	167
other	Vomiting	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	103	352	211
other	Constipation	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	119	376	167
other	Constipation	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	106	363	164
other	Constipation	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	101	352	155
other	Abdominal pain	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	106	376	155
other	Abdominal pain	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	84	363	122
other	Abdominal pain	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	91	352	149
other	Abdominal pain upper	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	46	376	55
other	Abdominal pain upper	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	47	363	54
other	Abdominal pain upper	Gastrointestinal disorders	Placebo Plus Taxane and Carboplatin	41	352	51
other	Dyspepsia	Gastrointestinal disorders	1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin	44	376	57
other	Dyspepsia	Gastrointestinal disorders	2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin	35	363	46

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00849667/events

API reference For AI assistants

Adverse events879

Sources 3

Read this list from software.